Metabolic dysfunction-associated steatotic liver disease (MASLD) — previously known as “non-alcoholic fatty liver disease” — affects about 25% of the global population.
New research offers hope for treating metabolic dysfunction-associated liver disease
- Post author:
- Post published:October 9, 2024
- Post category:uncategorized